Condition
Biliary Tract Adenocarcinoma
Total Trials
3
Recruiting
0
Active
0
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 2 (2)
Trial Status
Unknown3
Clinical Trials (3)
Showing 3 of 3 trials
NCT05350943Phase 2UnknownPrimary
HAIC Combined With Toripalimab and Donafenib for Advanced BTC
NCT04156958Phase 2UnknownPrimary
Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma
NCT01588860UnknownPrimary
Mutation Analysis and Copy Number Changes of KRAS and BRAF Gene in Taiwanese Cases of Biliary Tact Adenocarcinoma
Showing all 3 trials